OPEN END TURBO LONG - GLAUKOS Share Price

Certificat

DE000MG22ZZ5

Market Closed - Börse Stuttgart 20:58:46 17/05/2024 BST
1.79 EUR -2.72% Intraday chart for OPEN END TURBO LONG - GLAUKOS
Current month+203.39%
1 month+123.75%
Date Price Change
17/05/24 1.79 -2.72%
16/05/24 1.84 -6.60%
15/05/24 1.97 +15.20%
14/05/24 1.71 -0.58%
13/05/24 1.72 -10.42%

Delayed Quote Börse Stuttgart

Last update May 17, 2024 at 08:58 pm

More quotes

Static data

Product typeKnock-Out without Stop Loss
Buy / SellCALL
Underlying GLAUKOS CORPORATION
Issuer Morgan Stanley
WKN MG22ZZ
ISINDE000MG22ZZ5
Date issued 10/04/2024
Strike 90.91 $
Maturity Unlimited
Parity 10 : 1
Emission price 1.01
Emission volume N/A
Settlement cash
Currency EUR

Technical Indicators

Highest since issue 2.13
Lowest since issue 0.59

Company Profile

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.
Sector
-
More about the company

Ratings for Glaukos Corporation

Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings

Consensus: Glaukos Corporation

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
14
Last Close Price
109.8 USD
Average target price
112.5 USD
Spread / Average Target
+2.47%
Consensus